muromonab-CD3

CD3 Blocker Immunosuppressant — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

muromonab-CD3 is a drug in the CD3 Blocker Immunosuppressant class catalogued in DrugCentral. It was first approved by the FDA in 1992. Its mechanism of action is classified as CD3 Receptor Antagonists and CD3-directed Antibody Interactions. DrugCentral lists 1 molecular target, including CD3E|CD3G|CD3D. Recorded indications include Renal transplant rejection.

• Drug class: CD3 Blocker Immunosuppressant.
• Mechanism of action: CD3 Receptor Antagonists; CD3-directed Antibody Interactions.
• Molecular targets: CD3E|CD3G|CD3D (1 listed in DrugCentral).
• Indications: Renal transplant rejection.
• ATC code: L04AG01 (Monoclonal antibodies).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Renal transplant rejection

Mechanism & targets

• Mechanism of action (MoA): CD3 Receptor Antagonists; CD3-directed Antibody Interactions
• Established pharmacologic class: CD3 Blocker Immunosuppressant

Molecular targets (1)

Target	Gene	Action	Activity
T-cell surface glycoprotein CD3	CD3E|CD3G|CD3D	other	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1992-09-14	FDA	—	ORTHO BIOTECH

ATC classification

ATC code	Therapeutic hierarchy
L04AG01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Post transplant lymphoproliferative disorder	109.4

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 140608-64-6
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is muromonab-CD3 used for?

DrugCentral lists the following indications for muromonab-CD3: Renal transplant rejection.

How does muromonab-CD3 work?

Muromonab-CD3 is classified as CD3 Receptor Antagonists and CD3-directed Antibody Interactions; its molecular targets in DrugCentral include CD3E|CD3G|CD3D.

When was muromonab-CD3 first approved?

muromonab-CD3 was first approved by the FDA in 1992.

What drug class does muromonab-CD3 belong to?

muromonab-CD3 is in the CD3 Blocker Immunosuppressant class.

Sources

• DrugCentral drug card 5177 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201608 — compound record and bioactivity
• DrugBank DB00075 — drug record
• FDA UNII JGA39ICE2V — substance identity
• DailyMed: FDA labels for muromonab-CD3 — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.